See more : NKGen Biotech, Inc. Common Stock (NKGN) Income Statement Analysis – Financial Results
Complete financial analysis of Neurocrine Biosciences, Inc. (NBIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Neurocrine Biosciences, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Impala Platinum Holdings Limited (IMPUF) Income Statement Analysis – Financial Results
- AMBITION DX HOLDINGS Co., Ltd. (3300.T) Income Statement Analysis – Financial Results
- Teuza – A Fairchild Technology Venture Ltd. (TUZA.TA) Income Statement Analysis – Financial Results
- Toray Industries, Inc. (TRYIF) Income Statement Analysis – Financial Results
- DP Cap Acquisition Corp I (DPCSW) Income Statement Analysis – Financial Results
Neurocrine Biosciences, Inc. (NBIX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neurocrine.com
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.89B | 1.49B | 1.13B | 1.05B | 788.10M | 451.24M | 161.63M | 15.00M | 19.77M | 0.00 | 2.92M | 53.14M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 14.59M | 16.80M | 16.00M | 26.10M | 19.20M |
| Cost of Revenue | 39.70M | 23.20M | 14.30M | 10.10M | 7.40M | 4.89M | 1.25M | 35.90M | 33.80M | 14.40M | 13.80M | 11.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.20M | -2.10M | -1.70M | -1.30M | -1.00M |
| Gross Profit | 1.85B | 1.47B | 1.12B | 1.04B | 780.70M | 446.35M | 160.37M | -20.90M | -14.03M | -14.40M | -10.88M | 41.54M | 77.41M | 33.50M | 2.95M | 3.98M | 1.22M | 39.23M | 123.89M | 85.18M | 139.08M | 18.05M | 41.24M | 16.79M | 18.90M | 17.70M | 27.40M | 20.20M |
| Gross Profit Ratio | 97.90% | 98.44% | 98.74% | 99.03% | 99.06% | 98.92% | 99.22% | -139.33% | -70.97% | 0.00% | -372.76% | 78.17% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 115.07% | 112.50% | 110.63% | 104.98% | 105.21% |
| Research & Development | 565.00M | 463.80M | 328.10M | 275.00M | 200.00M | 160.52M | 121.83M | 94.29M | 81.49M | 46.43M | 39.25M | 37.16M | 30.95M | 31.15M | 35.81M | 55.29M | 81.99M | 97.68M | 106.63M | 115.07M | 177.27M | 108.94M | 74.27M | 40.23M | 29.20M | 21.80M | 19.90M | 12.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.54M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -82.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 887.60M | 752.70M | 583.30M | 433.30M | 354.10M | 248.93M | 169.91M | 68.08M | 32.48M | 17.99M | 13.35M | 13.44M | 12.46M | 16.07M | 14.83M | 20.24M | 37.48M | 54.87M | 42.33M | 22.44M | 20.59M | 12.72M | 10.86M | 9.96M | 7.50M | 6.60M | 5.70M | 3.70M |
| Other Expenses | 143.90M | 0.00 | 105.30M | 164.50M | 154.27M | 0.00 | -20.00K | 13.00K | 11.00K | 18.00K | 16.00K | 14.00K | 42.23M | 73.29M | 70.99M | 15.74M | 94.00M | 90.96M | 97.44M | 87.91M | 80.57M | 96.58M | 0.00 | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| Operating Expenses | 1.60B | 1.22B | 911.40M | 708.30M | 554.10M | 409.46M | 291.73M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 52.39M | 38.80M | 30.10M | 26.90M | 17.30M |
| Cost & Expenses | 1.64B | 1.24B | 925.70M | 718.40M | 561.50M | 414.35M | 292.99M | 162.37M | 113.97M | 64.41M | 52.60M | 51.69M | 43.41M | 47.22M | 50.64M | 91.27M | 213.47M | 152.55M | 148.96M | 137.51M | 197.87M | 121.66M | 85.12M | 50.19M | 36.70M | 28.40M | 25.60M | 16.30M |
| Interest Income | 0.00 | 11.20M | 3.80M | 12.60M | 19.21M | 0.00 | 0.00 | 2.84M | 1.93M | 629.00K | 400.00K | 489.00K | 435.00K | 397.00K | 691.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.60M | 7.10M | 25.80M | 32.80M | 32.00M | 30.53M | 19.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.30M | 15.60M | 10.90M | 8.60M | 7.45M | 4.02M | 2.40M | 1.50M | 1.01M | 827.00K | 671.00K | 657.00K | 694.00K | 1.44M | 3.18M | 7.61M | 9.40M | 10.57M | 10.09M | 7.08M | 3.69M | 3.10M | 2.65M | 2.20M | 2.10M | 1.70M | 1.30M | 1.00M |
| EBITDA | 358.00M | 264.60M | 218.70M | 336.10M | 226.60M | 56.40M | -120.62M | -139.59M | -87.92M | -63.58M | -49.01M | 2.11M | 34.62M | -13.72M | -47.86M | -73.98M | -193.97M | -102.75M | -14.98M | -45.25M | -55.10M | -100.52M | -41.23M | -33.40M | -17.80M | -10.70M | 1.80M | 3.90M |
| EBITDA Ratio | 18.97% | 16.73% | 18.33% | 31.31% | 28.75% | 8.18% | -81.29% | -1,024.27% | -503.13% | 0.00% | -1,824.25% | -3.98% | 39.32% | -36.67% | -1,501.32% | -1,650.74% | -8,891.99% | -261.89% | -12.09% | -52.97% | -52.62% | -558.23% | -101.02% | -236.15% | -107.14% | -20.63% | -11.88% | 2.60% |
| Operating Income | 250.90M | 249.00M | 196.90M | 318.90M | 219.15M | 36.90M | -131.36M | -147.37M | -94.20M | -64.41M | -49.68M | 1.45M | 33.92M | -13.72M | -53.67M | -87.30M | -212.24M | -113.32M | -25.07M | -52.33M | -58.79M | -103.62M | -43.88M | -35.60M | -19.90M | -12.40M | 500.00K | 2.90M |
| Operating Income Ratio | 13.30% | 16.73% | 17.37% | 30.49% | 27.81% | 8.18% | -81.27% | -982.48% | -476.51% | 0.00% | -1,701.88% | 2.72% | 43.82% | -40.96% | -1,817.47% | -2,196.18% | -17,340.03% | -288.82% | -20.24% | -61.44% | -42.27% | -574.20% | -106.40% | -244.04% | -118.45% | -77.50% | 1.92% | 15.10% |
| Total Other Income/Expenses | 81.20M | -35.10M | -1.10M | -56.30M | -25.80M | -15.05M | -11.18M | 6.28M | 5.27M | 3.87M | 3.59M | 3.58M | 3.65M | 5.75M | 2.63M | -1.32M | 4.94M | 6.11M | 2.88M | 6.64M | 28.69M | 9.08M | 7.09M | 7.10M | 200.00K | -7.40M | 4.80M | 3.20M |
| Income Before Tax | 332.10M | 213.90M | 101.40M | 106.70M | 46.50M | 21.84M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -88.61M | -88.61M | -207.30M | -107.21M | -22.19M | -45.69M | -30.10M | -94.54M | -36.79M | -28.51M | -19.70M | -19.80M | 5.30M | 6.10M |
| Income Before Tax Ratio | 17.60% | 14.37% | 8.95% | 10.20% | 5.90% | 4.84% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -3,000.78% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.65% | -21.64% | -523.89% | -89.21% | -195.41% | -117.26% | -123.75% | 20.31% | 31.77% |
| Income Tax Expense | 82.40M | 59.40M | 11.80M | -300.60M | 9.50M | 730.00K | 17.10M | -7.72M | -6.27M | -4.68M | -4.24M | -4.22M | -4.26M | 0.00 | 173.00K | 1.32M | -4.94M | 0.00 | 0.00 | 79.00K | 158.00K | -9.08M | 120.00K | 302.00K | -3.10M | 7.60M | 200.00K | 200.00K |
| Net Income | 249.70M | 154.50M | 89.60M | 407.30M | 37.00M | 21.11M | -142.54M | -141.09M | -88.93M | -60.54M | -46.09M | 5.03M | 37.57M | -7.97M | -51.04M | -88.61M | -207.30M | -107.21M | -22.19M | -45.77M | -30.26M | -94.54M | -36.91M | -28.81M | -16.80M | -20.00M | 5.10M | 5.90M |
| Net Income Ratio | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | 4.68% | -88.19% | -940.60% | -449.84% | 0.00% | -1,578.97% | 9.46% | 48.53% | -23.78% | -1,728.34% | -2,229.26% | -16,936.19% | -273.25% | -17.91% | -53.74% | -21.75% | -523.89% | -89.50% | -197.48% | -100.00% | -125.00% | 19.54% | 30.73% |
| EPS | 2.56 | 1.61 | 0.95 | 4.37 | 0.40 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.68 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.60 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.30 | 0.39 |
| EPS Diluted | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 | 0.22 | -1.62 | -1.63 | -1.05 | -0.81 | -0.69 | 0.08 | 0.67 | -0.15 | -1.30 | -2.30 | -5.45 | -2.84 | -0.58 | -1.26 | -0.93 | -3.10 | -1.42 | -1.30 | -0.88 | -1.10 | 0.28 | 0.36 |
| Weighted Avg Shares Out | 97.70M | 95.80M | 94.60M | 93.10M | 91.63M | 95.40M | 87.99M | 86.56M | 84.50M | 74.58M | 66.80M | 65.62M | 55.18M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 36.76M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 17.00M | 15.13M |
| Weighted Avg Shares Out (Dil) | 101.00M | 98.90M | 97.90M | 97.80M | 95.73M | 95.40M | 88.09M | 86.71M | 84.50M | 74.58M | 66.99M | 66.95M | 56.35M | 52.82M | 39.14M | 38.45M | 38.01M | 37.72M | 37.99M | 36.20M | 32.37M | 30.49M | 26.03M | 22.12M | 19.07M | 18.14M | 18.21M | 16.39M |
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents and Adults - Phase 2 Study for Modified-Release Hydrocortisone in Adults with Adrenal Insufficiency Demonstrated Participants Achieved Physiological Morning Cortisol Levels after 4 Weeks -...
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
CAHtalyst™ Study Baseline Characteristics Highlight the Need for New Treatment Options to Reduce Adrenal Androgens and Supraphysiologic Glucocorticoid Dosing in CAH Adult Patients Comprehensive Literature Review Identified Potential Psychological and Cognitive Impact of High Glucocorticoid Doses in CAH Patients SAN...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
SAN DIEGO , May 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants....
Nxera Pharma's partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
Tokyo, Japan and Cambridge, UK, 9 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) notes that its partner Neurocrine Biosciences Inc. (“Neurocrine”; Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, announced that it has initiated its Phase 1...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
SAN DIEGO , May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants....
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
SAN DIEGO , May 7, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m.
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
CAHtalyst™ Pediatric and CAHtalyst™ Adult Baseline Characteristics Data in Congenital Adrenal Hyperplasia Phase 2 (CHAMPAIN) Clinical Study Data for Modified-Release Hydrocortisone (Chronocort®/Efmody®) in Adrenal Insufficiency Phase 3 Extension Study Data for Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia SAN DIEGO ,...
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
Approximately 600,000 people in the United States live with tardive dyskinesia (TD), and about 65% have not yet been diagnosed1-3 The diagnosis rate can be improved by increasing routine TD screenings in people treated with antipsychotic medication4 SAN DIEGO ,...
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
Nvidia stock along with four other leading stocks are in or near buy areas as the market rally appears to be picking up steam.
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
CAHtalyst™ Pediatric Study Baseline Characteristics Data Highlight Need for Novel Treatments in Children and Adolescents with Congenital Adrenal Hyperplasia (CAH) CAHtalog™ Registry Data of Glucocorticoid Treatment Patterns in Pediatric and Adult Patients Illustrates the Challenges of Long-Term CAH Management SAN...
Source: https://incomestatements.info
Category: Stock Reports